Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/eye.2015.259 http://scihub22266oqcxt.onion/10.1038/eye.2015.259 C4791706!4791706!26681145     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26681145&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eye+(Lond) 2016 ; 30 (3): 463-72 Nephropedia Template TP {{tp|p=26681145|t=2016. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab |pdf=|usr=}}{{26681145}} gab.com Text Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab JO: Eye (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=26681145 #FOAvip Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0?mm?Hg in the non-bevacizumab group and 40.8±11.5?mm?Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8?mm?Hg in the non-bevacizumab group and 15.3±8.0?mm?Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P<0.001) in bevacizumab treated NVG eyes. Conclusions: Although bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP. Twit Text FOAVip Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab ????Eye (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=26681145 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26681145 #FOAvip English Wikipedia <ref>{{Cite pmid|26681145}}</ref> Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab #MMPMID26681145 Olmos LC; Sayed MS; Moraczewski AL; Gedde SJ; Rosenfeld PJ; Shi W; Feuer WJ; Lee RK Eye (Lond) 2016[Mar]; 30 (3): 463-72 PMID26681145show ga Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0?mm?Hg in the non-bevacizumab group and 40.8±11.5?mm?Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8?mm?Hg in the non-bevacizumab group and 15.3±8.0?mm?Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P<0.001) in bevacizumab treated NVG eyes. Conclusions: Although bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP. äLong-term outcomes of neovascular glaucoma treated with and without in(epmc).pdf DeepDyve Pubget Overpricing